189 related articles for article (PubMed ID: 22677701)
1. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
Gregory DL; Hicks RJ; Hogg A; Binns DS; Shum PL; Milner A; Link E; Ball DL; Mac Manus MP
J Nucl Med; 2012 Jul; 53(7):1007-15. PubMed ID: 22677701
[TBL] [Abstract][Full Text] [Related]
2. (18)F-FDG PET provides high-impact and powerful prognostic stratification in staging newly diagnosed non-small cell lung cancer.
Hicks RJ; Kalff V; MacManus MP; Ware RE; Hogg A; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1596-604. PubMed ID: 11696627
[TBL] [Abstract][Full Text] [Related]
3. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study.
Kalff V; Hicks RJ; MacManus MP; Binns DS; McKenzie AF; Ware RE; Hogg A; Ball DL
J Clin Oncol; 2001 Jan; 19(1):111-8. PubMed ID: 11134203
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
[TBL] [Abstract][Full Text] [Related]
5. Prognostic value of metabolic tumor burden from (18)F-FDG PET in surgical patients with non-small-cell lung cancer.
Zhang H; Wroblewski K; Liao S; Kampalath R; Penney BC; Zhang Y; Pu Y
Acad Radiol; 2013 Jan; 20(1):32-40. PubMed ID: 22999369
[TBL] [Abstract][Full Text] [Related]
6. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification.
Hicks RJ; Kalff V; MacManus MP; Ware RE; McKenzie AF; Matthews JP; Ball DL
J Nucl Med; 2001 Nov; 42(11):1605-13. PubMed ID: 11696628
[TBL] [Abstract][Full Text] [Related]
7. Prospective Study of Serial Imaging Comparing Fluorodeoxyglucose Positron Emission Tomography (PET) and Fluorothymidine PET During Radical Chemoradiation for Non-Small Cell Lung Cancer: Reduction of Detectable Proliferation Associated With Worse Survival.
Everitt S; Ball D; Hicks RJ; Callahan J; Plumridge N; Trinh J; Herschtal A; Kron T; Mac Manus M
Int J Radiat Oncol Biol Phys; 2017 Nov; 99(4):947-955. PubMed ID: 29063854
[TBL] [Abstract][Full Text] [Related]
8. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
9. Prognostic value of whole-body total lesion glycolysis at pretreatment FDG PET/CT in non-small cell lung cancer.
Chen HH; Chiu NT; Su WC; Guo HR; Lee BF
Radiology; 2012 Aug; 264(2):559-66. PubMed ID: 22692034
[TBL] [Abstract][Full Text] [Related]
10. [Impact of positron emission tomography on clinical management of potentially resectable non-small-cell lung cancer: a French prospective multicenter study].
Margery J; Milleron B; Vaylet F; Grahek D; Lebeau B; Mangiapan G; Bonardel G; de Labriolle-Vaylet C; Meignan M; Carette MF; Talbot JN; Housset B
Rev Pneumol Clin; 2010 Oct; 66(5):313-20. PubMed ID: 21087727
[TBL] [Abstract][Full Text] [Related]
11. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer.
Davey K; Heriot AG; Mackay J; Drummond E; Hogg A; Ngan S; Milner AD; Hicks RJ
Dis Colon Rectum; 2008 Jul; 51(7):997-1003. PubMed ID: 18461399
[TBL] [Abstract][Full Text] [Related]
12. Impact of Staging With Positron-emission Tomography (PET) and Comorbidities on Management and Survival of American Veterans With Stage I-III Non-Small Cell Lung Cancer.
Raghunathan R; Cease K; Troeschel S; Zhao L; Gross M; Chen G; Chopra V; Ramnath N
Am J Clin Oncol; 2018 May; 41(5):513-518. PubMed ID: 27322696
[TBL] [Abstract][Full Text] [Related]
13. Diffusion-weighted MRI versus 18F-FDG PET/CT: performance as predictors of tumor treatment response and patient survival in patients with non-small cell lung cancer receiving chemoradiotherapy.
Ohno Y; Koyama H; Yoshikawa T; Matsumoto K; Aoyama N; Onishi Y; Sugimura K
AJR Am J Roentgenol; 2012 Jan; 198(1):75-82. PubMed ID: 22194481
[TBL] [Abstract][Full Text] [Related]
14. Volume-based parameters of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography improve outcome prediction in early-stage non-small cell lung cancer after surgical resection.
Hyun SH; Choi JY; Kim K; Kim J; Shim YM; Um SW; Kim H; Lee KH; Kim BT
Ann Surg; 2013 Feb; 257(2):364-70. PubMed ID: 22968069
[TBL] [Abstract][Full Text] [Related]
15. Value of metabolic tumor volume on repeated 18F-FDG PET/CT for early prediction of survival in locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy.
Huang W; Fan M; Liu B; Fu Z; Zhou T; Zhang Z; Gong H; Li B
J Nucl Med; 2014 Oct; 55(10):1584-90. PubMed ID: 25214640
[TBL] [Abstract][Full Text] [Related]
16. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J; Grutters J; Wanders R; Boersma L; Oellers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Fatah SA; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2009 Mar; 45(4):588-95. PubMed ID: 19046631
[TBL] [Abstract][Full Text] [Related]
17. Impact of 18F-FDG PET/CT in the treatment of patients with non-small cell lung cancer.
Taus Á; Aguiló R; Curull V; Suárez-Piñera M; Rodríguez-Fuster A; Rodríguez de Dios N; Pijuan L; Zuccarino F; Vollmer I; Sánchez-Font A; Belda-Sanchis J; Arriola E
Arch Bronconeumol; 2014 Mar; 50(3):99-104. PubMed ID: 24360985
[TBL] [Abstract][Full Text] [Related]
18. F-18 fluorodeoxyglucose positron emission tomography staging in radical radiotherapy candidates with nonsmall cell lung carcinoma: powerful correlation with survival and high impact on treatment.
Mac Manus MP; Hicks RJ; Ball DL; Kalff V; Matthews JP; Salminen E; Khaw P; Wirth A; Rischin D; McKenzie A
Cancer; 2001 Aug; 92(4):886-95. PubMed ID: 11550162
[TBL] [Abstract][Full Text] [Related]
19. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
20. PET/CT using 18F-FDG in suspected lung cancer recurrence: diagnostic value and impact on patient management.
Keidar Z; Haim N; Guralnik L; Wollner M; Bar-Shalom R; Ben-Nun A; Israel O
J Nucl Med; 2004 Oct; 45(10):1640-6. PubMed ID: 15471827
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
